Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Bleomycin + CBP501|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CBP501||CBP-501|CBP 501||CHK1 Inhibitor 15||CBP501 is a peptide drug that inhibits the activity of several kinases responsible for phosphorylation of CDC25C, including MAPKAP-K2, C-Tak1, and CHK1, resulting in disruption of the G2 checkpoint and potentially leading to cell-cycle arrest and increased tumor cell death (PMID: 17237275, PMID: 29088764).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||pancreatic cancer||not applicable||Bleomycin + CBP501||Preclinical - Cell culture||Actionable||In a preclinical study, the combination of Blenoxane (bleomycin) and CBP501 resulted in increased cell death compared to Blenoxane (bleomycin) alone in a human pancreatic cancer cell line in culture (PMID: 17237275).||17237275|
|Unknown unknown||colorectal cancer||not applicable||Bleomycin + CBP501||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with the combination of Blenoxane (bleomycin) and CBP501 resulted in enhanced tumor growth inhibition in cell line xenograft models of colorectal cancer, compared to either agent alone (PMID: 17237275).||17237275|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|